NKP-1339 (Synonyms: KP1339) |
| Katalog-Nr.GC19263 |
NKP-1339 (IT-139; KP-1339) ist das erste Antikrebsmittel seiner Klasse auf Rutheniumbasis in der Entwicklung gegen soliden Krebs mit begrenzten Nebenwirkungen. NKP-1339 induziert den G2/M-Zellzyklusarrest, die Blockierung der DNA-Synthese und die Induktion der Apoptose Über den mitochondrialen Weg. NKP-1339 hat ein hohes Tumor-Targeting-Potenzial, bindet stark an Serumproteine wie Albumin und Transferrin und wird im reduktiven Tumormilieu aktiviert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 197723-00-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.
References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *